PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer

被引：0
|
作者：
Hou, Zhenlin
Jiang, Wu
Tang, Jinghua
Xiao, Binyi
Li, Yuan
Li, Dandan
Zhang, Xiaoshi
Pan, Zhi-Zhong
Ding, Peirong
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Biotherapy Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3637
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MSI plus STAGE II/III COLON CANCER PATIENTS BENEFIT FROM CAPECITABINE ADJUVANT MONOTHERAPY
    Dimovski, Aleksandar
    Matevska, Nadica
    Eftimov, Aleksandar
    Nestorovska, Aleksandra Kapedanovska
    Petrusevska, Natalija Angelovska
    Angelovska, Biljana
    Jashar, Djingis
    Mitrevski, Nikola
    Josifovski, Toni
    ANNALS OF ONCOLOGY, 2012, 23 : 106 - 106
  • [22] PD-1 antibody combined with COX inhibitor in MSI-h/dMMR or high TMB colorectal cancer: A single arm phase II study.
    Wu, Zehua
    Deng, Yanhong
    Zhang, Jianwei
    Hu, Huabin
    Cai, Yue
    Ling, Jiayu
    Deng, Ru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [23] Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study
    Hartung, G
    Hofheinz, RD
    Dencausse, Y
    Sturm, J
    Kopp-Schneider, A
    Dietrich, G
    Fackler-Schwalbe, I
    Bornbusch, D
    Gonnermann, M
    Wojatschek, C
    Lindemann, W
    Eschenburg, H
    Jost, K
    Edler, L
    Hochhaus, A
    Queisser, W
    ONKOLOGIE, 2005, 28 (6-7): : 347 - 350
  • [24] Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
    Yang, Renfang
    Wu, Tao
    Yu, Jiehai
    Cai, Xinyi
    Li, Guoyu
    Li, Xiangshu
    Huang, Weixin
    Zhang, Ya
    Wang, Yuqin
    Yang, Xudong
    Ren, Yongping
    Hu, Ruixi
    Feng, Qing
    Ding, Peirong
    Zhang, Xuan
    Li, Yunfeng
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer
    Starling, Naureen
    Neumann, Katerina
    Colwell, Bruce
    Strickler, John H.
    Benson, Al Bowen, III
    Asselah, Jamil
    Komatsu, Yoshito
    Marques, Sara
    Edwards, Ken
    O'Donnell, Sean Barton
    Stjepanovic, Neda
    Seligmann, Jenny F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS240 - TPS240
  • [26] Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer
    Cercek, Andrea
    Bachet, Jean-Baptiste
    Capdevila, Jaume
    Starling, Naureen
    Xueyu Chen, Eric
    Di Bartolomeo, Maria
    Yoshino, Takayuki
    Vlahovic, Gordana
    Zografos, Eleftherios
    O'Donnell, Sean
    Szijgyarto, Zsolt
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences
    Song, Geum Jong
    Choi, Yoon Young
    JOURNAL OF GASTRIC CANCER, 2024, 24 (03) : 243 - 245
  • [28] Toripalimab (anti-PD-1) plus recombinant human endostatin as adjuvant therapy in patients with resected stage III melanoma: Interim analysis of an open-label phase II trial.
    Hu, Xianglin
    Xu, Yu
    Sun, Yang-bai
    Yang, Ling-ge
    Zheng, Bi-qiang
    Sun, Zheng-Wang
    Chen, Yong
    Yan, Wangjun
    Wang, Chun-Meng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
    Yoshida, M.
    Ishiguro, M.
    Ikejiri, K.
    Mochizuki, I.
    Nakamoto, Y.
    Kinugasa, Y.
    Takagane, A.
    Endo, T.
    Shinozaki, H.
    Takii, Y.
    Mochizuki, H.
    Kotake, K.
    Kameoka, S.
    Takahashi, K.
    Watanabe, T.
    Watanabe, M.
    Boku, N.
    Tomita, N.
    Nakatani, E.
    Sugihara, K.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1743 - 1749
  • [30] Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer
    Takagane, A.
    Takiuchi, H.
    Ikejiri, K.
    Mochizuki, I.
    Mochizuki, H.
    Kotake, K.
    Kameoka, S.
    Takahashi, K.
    Watanabe, T.
    Watanabe, M.
    Boku, N.
    Tomita, N.
    Matsubara, Y.
    Sugihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345